Biogen Idec to buy Stromedix for up to $562M Mass High Tech In August 2008, Stromedix won orphan drug status from the US Food and Drug Administration for STX-100, as a treatment for chronic allograft nephropathy, a cause of transplant failure in patients with kidney transplants. Michael Gilman, founder and CEO ... |
